Recro Pharma Культура компании

Mr. Frederick H. Graff, also known as Fred, has been the Chief Commercial Officer at Recro Pharma, Inc., since February 16, 2016. Mr. Graff has more than 25 years of experience in commercial sales and marketing of pharmaceutical products. He has extensive experience launching and co-promoting new pharmaceutical products in both the specialty pharmaceutical and primary care sectors, including with partners. He began his career at Rhone Poulenc Rorer where he progressed through sales and field management to key headquarters sales support positions, culminating in his role as Director of Sales, US Cardiovascular Division, leading a 500+ person sales force. He served as Vice President of Commercial Operations at MAP Pharmaceuticals, Inc., since August 2011. He was instrumental in developing a joint commercial launch plan between MAP and Allergan that included product pricing, contract strategy, trade strategy, product positioning and messaging and sample policy. Mr. Graff lead the establishment of a commercial sales organization and develops a U.S. launch strategy for LEVADEX(R) orally inhaled migraine drug in anticipation of potential approval by the U.S. Food and Drug Administration (FDA). He designed and built a fully integrated sales organization which generated over $1 billion in annual sales revenue. He spent the next 10 years of his career at Sepracor Pharmaceuticals. He served as Senior Vice President of Sales at Sunovion Pharmaceuticals Inc., (formerly, Sepracor Inc.) until October 2007 and served as its Vice President of sales. He also spearheaded five sales force expansions over an eight-year period that included the launch of Lunesta(R), a CNS (Central Nervous System) product, into specialty and primary care markets. In addition, he played an integral role on the senior leadership team at Sepracor developing its commercial capability and championing key organizational development initiatives necessary to build and sustain a high performance sales organization. He founded Graff & Associates in 2013, where he provided strategic consultancy services to a variety of life science companies. He holds a BA in Political Science from the University of Arizona.

Mr. Ryan D. Lake, CPA, has been Chief Accounting Officer of Recro Pharma, Inc. since June 5, 2017. Mr. Lake joined Recro Pharma from Aspire Bariatrics, Inc., where he served as Chief Financial Officer and Vice President of Finance for two years. From 2012 to 2015, he held executive management and senior finance positions including Director of the Natural Materials Division, Controller and Senior Director of Finance, at DSM Biomedical, a division of Royal DSM. He served as Director of Finance, Principal Financial Officer and Principal Accounting Officer at Kensey Nash Corporation since October 2008 until its acquisition by Royal DSM in 2012. He served as Director of Accounting at Kensey Nash Corporation since 2007. From 2005 to 2007, Mr. Lake served as Senior Accounting and Compliance Manager of Kensey Nash Corporation. From 2003 to 2005, he served as General Accounting Manager of Kensey Nash Corporation. He joined Kensey Nash Corporation in 2002. From 1999 to 2002, he served as an Accounting and Audit Senior at the public accounting firm Deloitte & Touche, LLP. Prior to, he served as an Accountant of Nihill & Riedley, P.C. Mr. Lake holds a B.S. degree in Accounting from West Chester University of Pennsylvania and is a Certified Public Accountant in the Commonwealth of Pennsylvania.

Mr. Michael Celano, also known as Mike, CPA, was the Chief Financial Officer of Recro Pharma, Inc. Mr. Celano has served in a Part-Time capacity, as the Chief Financial Officer of Makindus since 2015. He has over 35 years of financial leadership experience in the life sciences and biopharmaceutical industries. He served as the Chief Financial Officer of DrugScan, a laboratory services company from 2013 to 2015. He served as the Chief Financial Officer of Kensey Nash Corporation from March 10, 2009 to 2012. He served as Managing Director of Life Sciences National Practice Group at Aon Risk Services Companies, Inc. from August 2007 to December 2008. He served as the Chief Financial Officer and Vice President of Finance at BioRexis Pharmaceuticals Corporation, a biopharmaceutical company from July 2004 to May 2007. He has extensive experience in life sciences where he spent 24 years in public accounting as a Partner with KPMG LLP, where he was an in charge of its Mid-Atlantic Life Sciences Practice from June 2002 to August 2004 and was a Co-Leader of its National Life Science Practice. Prior to joining KPMG, he was Co-Leader of the Life Science Practice and Partner for Arthur Andersen LLP for several years. He served more than forty life sciences clients and was the Lead Audit Partner for sixteen different public life sciences companies. From 1980 to 2004, he worked at Arthur Andersen/KPMG. He was the Lead Partner on twenty-two initial public offerings. He worked on over 100 public offerings and over sixty corporate partner and merger/acquisition transactions. He has been a Director of Performance Health Holdings Corp. since September 2015. He has been Director of OraSure Technologies, Inc. since 2003. He serves on the Board of a publicly held medical diagnostics company. He served as a Board Member of the Greater Philadelphia Venture Group. He is a Co-Founder and Advisor of the Philadelphia/Princeton Chapter of the Association of Bioscience Financial Officers. He served as Treasurer of The Pennsylvania Biotechnology Association. From 2003 to 2004, he served as the Chairman of the National Conference for the Association of Bioscience Financial Officers. He served as the Chairman of the Mid-Atlantic Venture Conference (the First Non-Venture Capital/Investment Banker to chair the conference). He served as a Director of The Pennsylvania Biotechnology Association. Mr. Celano is a Certified Public Accountant and holds a B.S. degree in Accounting from St. Joseph's University.

Mr. Randall J. Mack, also known as Randy, has been Senior Vice President of Development and Secretary at RECRO Pharma, Inc. since 2008. Mr. Mack served as Vice President, Project Management and Operations of Adolor Corporation from July 6, 2005 to 2008 and was responsible for creating and executing projects across its clinical and product development teams. Mr. Mack served as the vice president of clinical development at Auxilium Pharmaceuticals where he was responsible for all functional areas of the development programs, including the design and execution of clinical trials and the preparation of the clinical components of US and European regulatory submissions. Mr. Mack's tenure in the biopharmaceutical industry also includes work with Abbott Laboratories and Harris Laboratories, where he garnered experience in business development, research, project management and operations. Mr. Mack earned his Bachelor of Science in Biology and Chemistry from the University of Nebraska-Lincoln.

Randy Mack serves as the Senior Vice President, Development of Recro Pharma, Inc.. Randy started at Recro Pharma, Inc. in August of 2008. Randy currently resides in Greater Philadelphia Area.

Greg Gangemi serves as the Vice President of Sales of Recro Pharma, Inc.. Greg started at Recro Pharma, Inc. in August of 2017. Greg currently resides in Greater Boston Area.

Norberto Alberto serves as the Regional Medical Director of Recro Pharma, Inc.. Norberto started at Recro Pharma, Inc. in June of 2017. Norberto currently resides in Greater New York City Area.

Ryan Lake serves as the Chief Financial Officer of Recro Pharma, Inc.. Ryan started at Recro Pharma, Inc. in January of 2018. Ryan currently resides in the Greater Philadelphia Area.

Scott Brewster serves as the National Director, Trade and Distribution of Recro Pharma, Inc.. Scott started at Recro Pharma, Inc. in October of 2018. Scott currently resides in the Dover, Delaware Area.